Avis et décisions de la HAS
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
Voir aussi
Avis et décisions de la HAS
17/11/2017
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
hw4gjaUZYZxpBQjM
